By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Mitotic inhibitors > Eribulin > Eribulin Dosage
Mitotic inhibitors
https://themeditary.com/dosage-information/eribulin-dosage-11191.html

Eribulin Dosage

Drug Detail:Eribulin (Eribulin [ e-rib-ue-lin ])

Drug Class: Mitotic inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Breast Cancer

1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8 of a 21-day cycle

Comments:

  • This drug should be administered under the supervision of a qualified physician experienced in the appropriate use of cytotoxic medicinal products.
  • Patients may experience nausea or vomiting. Antiemetic prophylaxis including corticosteroids should be considered.
  • Peripheral neuropathy should be assessed and complete blood cell counts should be obtained prior to each dose.

Use: For the treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Renal Dose Adjustments

  • Mild renal impairment (CrCl 50 to 80 mL/min): No adjustment recommended
  • Moderate renal impairment (CrCl 30 to 50 mL/min): 1.1 mg/m2 IV over 2 to 5 minutes on days 1 and 8 of a 21-day cycle.
  • Severe renal impairment (CrCl less than 30 mL/min): Data not available

Liver Dose Adjustments

  • Mild liver impairment (Child-Pugh A): 1.1 mg/m2 intravenously over 2 to 5 minutes on days 1 and 8 of a 21-day cycle
  • Moderate liver impairment (Child-Pugh B): 0.7 mg/m2 intravenously over 2 to 5 minutes on days 1 and 8 of a 21-day cycle
  • Severe liver impairment (Child-Pugh C): Data not available

Dose Adjustments

PLEASE NOTE:

  • In the EU the recommended dose refers to the base of the active substance (eribulin). Calculation of the individual dose to be administered to a patient should be based on the strength of the ready to use solution that contains 0.44 mg/mL eribulin.
  • In some other regions (e.g., the US and other countries), the recommended dose is based on the salt form (eribulin mesylate).

This drug should not be administered on day 1 or day 8 if:
  • The patient is experiencing grade 3 or 4 non-hematological toxicities
  • The absolute neutrophil count (ANC) is less than 1000 cells/mm3
  • Platelets are less than 75,000/mm3.

The day 8 dose may be delayed for a maximum of 1 week if:
  • Toxicities do not resolve or improve to less than or equal to grade 2 by day 15, the dose should be omitted
  • Toxicities resolve or improve to less than or equal to grade 2 severity by day 15, this drug should be administered at a reduced dose and the next cycle should be initiated at least 2 weeks later

The 1.4 mg/m2 dose should be permanently reduced to 1.1 mg/m2 for any of the following:
  • Absolute neutrophil count (ANC) less than 500 cells/mm3 for more than 7 days
  • ANC less than 1000 cells/mm3 with fever or infection
  • Platelets less than 25,000/mm3
  • Platelets less than 50,000/mm3 requiring transfusion
  • Non-hematologic grade 3 or 4 toxicities
  • Omission or delay of day 8 dose in previous cycle for toxicity

  • The occurrence of any adverse event requiring permanent dose reduction while receiving the 1.1 mg/m2 dose, the dose should be further reduced to 0.7 mg/m2.

  • The occurrence of any adverse event requiring permanent dose reduction while receiving the 0.7 mg/m2 dose, this drug should be discontinued.

The dose of this drug should not be re-escalated after it has been reduced.

Precautions

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Storage requirements:

  • The manufacturer product information should be consulted for recommended storage requirements.

Reconstitution/preparation techniques:
  • The dose should be diluted in up to 100 mL of sodium chloride 0.9% solution for injection. It should not be diluted in glucose 5% infusion solution.

IV compatibility:
  • This drug should not be diluted in or administered through an IV line containing dextrose solutions or mixed with any other medicinal agents.

General:
  • Good peripheral venous access or a patent central line should be obtained prior to administration.
  • If extravasation occurs, treatment should be symptomatic.

Monitoring:
  • A complete blood count is recommended prior to each dose and increased monitoring is recommended in patients who develop grade 3 or 4 cytopenias.
  • Patients should be closely monitored for the development of neuropathies.
  • Electrocardiogram (ECG) monitoring is recommended in patients at risk of developing QT interval prolongation. Use should be avoided in patients with congenital long QT syndrome.
  • Electrolyte abnormalities should be corrected prior to initiation of the dose and periodic monitoring of electrolytes is recommended during therapy.

Patient advice:
  • This drug can cause a decrease in white blood cell count (neutropenia). This can make you more likely to get serious infections that could lead to death. You may need treatment in the hospital with antibiotic medicines.
  • Call your healthcare provider right away if you develop any of these symptoms of infection while you are receiving this drug: Fever (temperature above 100.5F), chills, cough, burning or pain when you urinate.
  • This drug can cause numbness, tingling, or burning in your hands and feet (neuropathy). Tell your healthcare provider if you have any of these symptoms.
  • Tell your healthcare provider if you have liver or kidney problems, heart problems, including a problem called "congenital long QT syndrome", are pregnant or plan to become pregnant, are breastfeeding or planning to breastfeed.
  • The most common side effects of this drug are: Weakness or tiredness, hair loss, nausea, and constipation.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by